KLK3 and cancer: The proportion of patients with WHO’s cancer pain ladder score of 0 was numerically smaller (60% vs 75%) and the median PSA value (33.8 vs 17.3 ng/mL) was higher in the prior-chemo group than the no prior-chemo group.